LENZ Therapeutics, Inc. (LENZ)
NASDAQ: LENZ · Real-Time Price · USD
29.00
+0.48 (1.70%)
May 1, 2025, 4:00 PM EDT - Market closed
Company Description
LENZ Therapeutics, Inc. operates as a biopharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States.
Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia.
LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021.
The company was founded in 2013 and is headquartered in Solana Beach, California.
LENZ Therapeutics, Inc.
| Country | United States |
| Founded | 2019 |
| IPO Date | Jun 25, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Evert Schimmelpennink |
Contact Details
Address: 201 Lomas Santa Fe Drive, Suite 300 Solana Beach, California 92075 United States | |
| Phone | (858) 925-7000 |
| Website | lenz-tx.com |
Stock Details
| Ticker Symbol | LENZ |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001815776 |
| CUSIP Number | 52635N103 |
| ISIN Number | US52635N1037 |
| Employer ID | 84-4867570 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Evert B. Schimmelpennink | President, Chief Executive Officer, Secretary and Director |
| James W. McCollum | Co-Founder and Director |
| Daniel R. Chevallard CPA | Chief Financial Officer |
| Marc G. Odrich M.D. | Chief Medical Officer |
| Domenick Porfidia | Vice President of Sales |
| David Murphy | Vice President of Marketing |
| Breianna Bowen | Vice President of Human Resources |
| Shawn Olsson | Chief Commercial Officer |
| Marvin J. Garrett | Senior Vice President of Regulatory and Quality |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 28, 2025 | ARS | Filing |
| Apr 28, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 28, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 15, 2025 | 8-K | Current Report |
| Apr 14, 2025 | EFFECT | Notice of Effectiveness |
| Apr 14, 2025 | EFFECT | Notice of Effectiveness |
| Apr 14, 2025 | 424B5 | Filing |
| Apr 14, 2025 | 424B3 | Prospectus |
| Apr 9, 2025 | 424B3 | Prospectus |
| Apr 9, 2025 | 424B3 | Prospectus |